Anti-obese effect of glucosamine and chitosan oligosaccharide in high-fat diet-induced obese rats

Marine Drugs

Volumn 13, Issue 5, 2015, Pages 2732-2756

  Huang, Lanlan ^a   Chen, Jian ^a   Cao, Peiqiu ^a   Pan, Haitao ^a   Ding, Chen ^a   Xiao, Tiancun ^b,c   Zhang, Pengfei ^c   Guo, Jiao ^a   Su, Zhengquan ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Guangzhou Boxabio Tech Ltd   (China)

Author keywords

Anti obesity; COS1; COS2; GLC; LXR ; PPAR

Indexed keywords

CHITOSAN OLIGOSACCHARIDE; GLUCOSAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIGOSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; ANTIOBESITY AGENT; CHITOSAN; CHOLESTEROL; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; NR1H3 PROTEIN, RAT; ORPHAN NUCLEAR RECEPTOR;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOBESE EFFECT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DDX56 GENE; DIET INDUCED OBESITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DYSLIPIDEMIA; GENE; GENE EXPRESSION REGULATION; HEART; LIPID DIET; LIVER STRUCTURE; LXRA GENE; MALE; MOLECULAR WEIGHT; NONHUMAN; PPARY GENE; RAT; RGD1311874 GENE; SIGNAL TRANSDUCTION; WEIGHT GAIN; WHITE ADIPOSE TISSUE; ZFP354A GENE; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY WEIGHT; DRUG EFFECTS; METABOLISM; OBESITY; SPRAGUE DAWLEY RAT;

RATTUS;

ADIPOCYTES; ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; CELL DIFFERENTIATION; CHITOSAN; CHOLESTEROL; DIET, HIGH-FAT; GLUCOSAMINE; LIPOPROTEINS, LDL; LIVER X RECEPTORS; MALE; OBESITY; OLIGOSACCHARIDES; ORPHAN NUCLEAR RECEPTORS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84930648307     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md13052732     Document Type: Article

References (50)

1. WHO. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ. Tech. Rep. Ser. 2000, 894, 1-253.
2. Low, S.; Chin, M.C.; Deurenberg-Yap, M. Review on epidemic of obesity. Ann. Acad. Med. Singap. 2009, 38, 57-59.
3. Xi, B.; Liang, Y.; He, T.; Reilly, K.H.; Hu, Y.; Wang, Q.; Yan, Y.; Mi, J. Secular trends in the prevalence of general and abdominal obesity among Chinese adults, 1993-2009. Obes. Rev. 2012, 13, 287-296.
4. Lee, S.O.; Simons, A.L.; Murphy, P.A.; Hendrich, S. Soyasaponins lowered plasma cholesterol and increased fecal bile acids in female golden Syrian hamsters. Exp. Biol. Med. (Maywood) 2005, 230, 472-478.
5. Haslam, D.W.; James, W.P. Obesity. Lancet 2005, 366, 1197-1209.
6. Ahima, R.S. Digging deeper into obesity. J. Clin. Investig. 2011, 121, 2076-2079.
7. Reilly, J.J.; Methven, E.; McDowell, Z.C.; Hacking, B.; Alexander, D.; Stewart, L.; Kelnar, C.J. Health consequences of obesity. Arch. Dis. Child. 2003, 88, 748-752.
8. Younes, I.; Rinaudo, M. Chitin and Chitosan Preparation from Marine Sources. Structure, Properties and Applications. Mar. Drugs 2015, 13, 1133-1174.
9. Ju, C.; Yue, W.; Yang, Z.; Zhang, Q.; Yang, X.; Liu, Z.; Zhang, F. Antidiabetic effect and mechanism of chitooligosaccharides. Biol. Pharm. Bull. 2010, 33, 1511-1516.
10. Fernandes, J.C.; Sereno, J.; Garrido, P.; Parada, B.; Cunha, M.F.; Reis, F.; Pintado, M.E.; Santos-Silva, A. Inhibition of bladder tumor growth by chitooligosaccharides in an experimental carcinogenesis model. Mar. Drugs 2012, 10, 2661-2675.
11. Yang, Y.; Liu, M.; Gu, Y.; Lin, S.; Ding, F.; Gu, X. Effect of chitooligosaccharide on neuronal differentiation of PC-12 cells. Cell Biol. Int. 2009, 33, 352-356.
12. Niu, J; Lin, H.Z; Jiang, S.G; Chen, X; Wu, K.C; Liu, Y.J; Wang, S; Tian, L.X. Comparison of effect of chitin, chitosan, chitosan oligosaccharide and N-acetyl-D-glucosamine on growth performance, antioxidant defenses and oxidative stress status of Penaeus monodon. Aquaculture 2013, 372-375, 1-8.
13. Walsh, A.M.; Sweeney, T.; Bahar, B.; Flynn, B.; O'Doherty, J.V. The effect of chitooligosaccharide supplementation on intestinal morphology, selected microbial populations, volatile fatty acid concentrations and immune gene expression in the weaned pig. Animal 2012, 6, 1620-1626.
14. Kim, J.N.; Chang, I.Y.; Kim, H.I.; Yoon, S.P. Long-term effects of chitosan oligosaccharide in streptozotocin-induced diabetic rats. Islets 2009, 1, 111-116.
15. Yan, Y.; Wanshun, L.; Baoqin, H.; Bing, L.; Chenwei, F. Protective effects of chitosan oligosaccharide and its derivatives against carbon tetrachloride-induced liver damage in mice. Hepatol. Res. 2006, 35, 178-184.
16. Choi, C.R.; Kim, E.K.; Kim, Y.S.; Je, J.Y.; An, S.H.; Lee, J.D.; Wang, J.H.; Ki, S.S.; Jeon, B.T.; Moon, S.H.; et al. Chitooligosaccharides decreases plasma lipid levels in healthy men. Int. J. Food Sci. Nutr. 2012, 63, 103-106.
17. Sherman, A.L.; Ojeda-Correal, G.; Mena, J. Use of glucosamine and chondroitin in persons with osteoarthritis. PMR 2012, 4, S110-S116.
18. Reginster, J.Y.; Neuprez, A.; Lecart, M.P.; Sarlet, N.; Bruyere, O. Role of glucosamine in the treatment for osteoarthritis. Rheumatol. Int. 2012, 32, 2959-2967.
19. Liming, J.; Yan, Y.; Wanshun, L.; Baoqin, H.; Wenjie, T.; Shengdi, F. Protective effects of D-glucosamine against carbon tetrachloride-induced liver damage in mice. J. Zhengzhou Univ. (Med. Sci.) 2009, 44, 122-125.
20. Wendi, C.; Jinxin, C.; Chenwei, F.; Wanshun, L.; Baoqin, H. Effect of glucosamine on immune function of murine peritoneal macrophages. Chin. J. Biol. 2010, 23, 946-948.
21. Xin, C. Studies on antimicrobial effects of D-glucosamine hydrochloride. Fish. Sci. 2001, 20, 14-15.
22. Shintani, T.; Yamazaki, F.; Katoh, T.; Umekawa, M.; Matahira, Y.; Hori, S.; Kakizuka, A.; Totani, K.; Yamamoto, K.; Ashida, H. Glucosamine induces autophagy via an mTOR-independent pathway. Biochem. Biophys. Res. Commun. 2010, 391, 1775-1779.
23. Xing, R.; Liu, S.; Guo, Z.; Yu, H.; Li, C.; Ji, X.; Feng, J.; Li, P. The antioxidant activity of glucosamine hydrochloride in vitro. Bioorganic Med. Chem. 2006, 14, 1706-1709.
24. Hong, L.Z.; Li, J.; Schmidt-Kuntzel, A.; Warren, W.C.; Barsh, G.S. Digital gene expression for non-model organisms. Genome Res. 2011, 21, 1905-1915.
25. Tiirikka, T.; Siermala, M.; Vihinen, M. Clustering of gene ontology terms in genomes. Gene 2014, 550, 155-164.
26. Hong, M.G.; Pawitan, Y.; Magnusson, P.K.; Prince, J.A. Strategies and issues in the detection of pathway enrichment in genome-wide association studies. Hum. Genet. 2009, 126, 289-301.
27. Kanehisa, M.; Goto, S.; Sato, Y.; Kawashima, M.; Furumichi, M.; Tanabe, M. Data, information, knowledge and principle: Back to metabolism in KEGG. Nucleic Acids Res. 2014, 42, D199-D205.
28. Tao, Y.; Zhang, H.L.; Hu, Y.M.; Wan, S.; Su, Z.Q. Preparation of chitosan and water-soluble chitosan microspheres via spray-drying method to lower blood lipids in rats fed with high-fat diets. Int. J. Mol. Sci. 2013, 14, 4174-4184.
29. Zhang, H.L.; Zhong, X.B.; Tao, Y.; Wu, S.H.; Su, Z.Q. Effects of chitosan and water-soluble chitosan micro- and nanoparticles in obese rats fed a high-fat diet. Int. J. Nanomed. 2012, 7, 4069-4076.
30. Tan, S.; Gao, B.; Tao, Y.; Guo, J.; Su, Z.Q. Antiobese effects of capsaicin-chitosan microsphere (CCMS) in obese rats induced by high fat diet. J. Agric. Food Chem. 2014, 62, 1866-1874.
31. Cho, E.J.; Rahman, M.A.; Kim, S.W.; Baek, Y.M.; Hwang, H.J.; Oh, J.Y.; Hwang, H.S.; Lee, S.H.; Yun, J.W. Chitosan oligosaccharides inhibit adipogenesis in 3T3-L1 adipocytes. J. Microbiol. Biotechnol. 2008, 18, 80-87.
32. Kumar, S.G.; Rahman, M.A.; Lee, S.H.; Hwang, H.S.; Kim, H.A.; Yun, J.W. Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan oligosaccharides in ob/ob mice. Proteomics 2009, 9, 2149-2162.
33. Rahman, A.; Kumar, S.G.; Kim, S.W.; Hwang, H.J.; Baek, Y.M.; Lee, S.H.; Hwang, H.S.; Shon, Y.H.; Nam, K.S.; Yun, J.W. Proteomic analysis for inhibitory effect of chitosan oligosaccharides on 3T3-L1 adipocyte differentiation. Proteomics 2008, 8, 569-581.
34. Chawla, A.; Boisvert, W.A.; Lee, C.H.; Laffitte, B.A.; Barak, Y.; Joseph, S.B.; Liao, D.; Nagy, L.; Edwards, P.A.; Curtiss, L.K.; et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 2001, 7, 161-171.
35. Hayashi, K.; Ito, M. Antidiabetic action of low molecular weight chitosan in genetically obese diabetic KK-Ay mice. Biol. Pharm. Bull. 2002, 25, 188-192.
36. Sumiyoshi, M.; Kimura, Y. Low molecular weight chitosan inhibits obesity induced by feeding a high-fat diet long-term in mice. J. Pharm. Pharmacol. 2006, 58, 201-207.
37. Gottlicher, M.; Widmark, E.; Li, Q.; Gustafsson, J.A. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 1992, 89, 4653-4657.
38. Mitro, N.; Mak, P.A.; Vargas, L.; Godio, C.; Hampton, E.; Molteni, V.; Kreusch, A.; Saez, E. The nuclear receptor LXR is a glucose sensor. Nature 2007, 445, 219-223.
39. Edwards, P.A.; Kennedy, M.A.; Mak, P.A. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul. Pharmacol. 2002, 38, 249-256.
40. Gronemeyer, H.; Gustafsson, J.A.; Laudet, V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 2004, 3, 950-964.
41. Lee, C.H.; Olson, P.; Evans, R.M. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144, 2201-2207.
42. Gervois, P.; Fruchart, J.C.; Staels, B. Drug Insight: Mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3, 145-156.
43. Vuppalanchi, R.; Chalasani, N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009, 49, 306-317.
44. Rosen, E.D.; Spiegelman, B.M. PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 2001, 276, 37731-37734.
45. Millatt, L.J.; Bocher, V.; Fruchart, J.C.; Staels, B. Liver X receptors and the control of cholesterol homeostasis: Potential therapeutic targets for the treatment of atherosclerosis. Biochim. Biophys. Acta 2003, 1631, 107-118.
46. Rebe, C.; Filomenko, R.; Raveneau, M.; Chevriaux, A.; Ishibashi, M.; Lagrost, L.; Junien, J.L.; Gambert, P.; Masson, D. Identification of biological markers of liver X receptor (LXR) activation at the cell surface of human monocytes. PLoS ONE 2012, 7, e48738.
47. Chawla, A.; Repa, J.J.; Evans, R.M.; Mangelsdorf, D.J. Nuclear receptors and lipid physiology: Opening the X-files. Science 2001, 294, 1866-1870.
48. Yoshikawa, T.; Shimano, H.; Amemiya-Kudo, M.; Yahagi, N.; Hasty, A.H.; Matsuzaka, T.; Okazaki, H.; Tamura, Y.; Iizuka, Y.; Ohashi, K.; et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 2001, 21, 2991-3000.
49. Pawar, A.; Botolin, D.; Mangelsdorf, D.J.; Jump, D.B. The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression. J. Biol. Chem. 2003, 278, 40736-40743.
50. Schultz, J.R.; Tu, H.; Luk, A.; Repa, J.J.; Medina, J.C.; Li, L.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D.J.; et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14, 2831-2838.